In a move that promises to redefine the competitive landscape of the global biosimilars market, German healthcare titan Fresenius has announced an exclusive, decade-long development agreement with WuXi Biologics. This massive undertaking, unveiled on November 2, positions Fresenius to potentially more than double its current portfolio of 29 marketed and pipeline biosimilar molecules to as many as 66. By targeting originator drugs that command a collective market value exceeding €370 billion in list-price-based sales, Fresenius is signaling a aggressive shift toward total dominance in the biosimilars sector.
Industry analysts have characterized this deal as the largest development partnership in the history of the biosimilars industry. It represents a sophisticated "plug-and-play" model where Fresenius provides the strategic direction and commercial muscle, while WuXi Biologics serves as the specialized engine for research, development, and manufacturing.
The Strategic Framework: How the Deal Functions
The architecture of this partnership is designed for maximum efficiency and scalability. Rather than committing to a fixed, high-cost research pipeline, Fresenius retains the flexibility to curate its offerings. The company will evaluate potential biosimilar candidates against a rigid set of internal criteria, including market attractiveness, the technical risk profile of development, and the projected return on investment.
Under the agreement, Fresenius pays WuXi Biologics on a fee-for-service basis, ensuring that capital allocation remains tied strictly to the successful progression of selected programs. Critically, Fresenius secures exclusive global commercialization rights, including all marketing authorizations and the full economic value of the products it brings to market.
Furthermore, the operational control remains firmly in the hands of the German firm. Fresenius will dictate the manufacturing strategy for each product, with the flexibility to transition production to its internal powerhouse, mAbxience—a Spain-headquartered unit fully integrated into Fresenius Kabi. Meanwhile, WuXi Biologics will leverage its extensive, multi-continental infrastructure across Europe, the United States, China, and Singapore to drive the technical development phase.
Chronology of a Corporate Pivot
The path to this massive partnership was not accidental; it is the culmination of a deliberate, long-term strategic transformation at Fresenius.
- August 2022: Fresenius Kabi secures a majority stake in mAbxience, marking the company’s intent to pivot toward high-growth biopharmaceuticals.
- September 30, 2025: Fresenius completes the acquisition of the remaining 45% stake in mAbxience from Insud Pharma and Invim Corporativo, a deal valued at up to €750 million.
- October 1, 2025: Official announcement of the full consolidation of mAbxience, providing Fresenius with total control over its biosimilars manufacturing and development capabilities.
- December 2025: The company establishes an ambitious 2030 goal to double its Biopharma revenue compared to 2025 levels, targeting an EBIT margin of approximately 20%.
- November 2, 2026: Fresenius and WuXi Biologics announce the comprehensive 37-candidate development agreement, significantly accelerating the timeline to reach their 2030 objectives.
Supporting Data: Targeting the Blockbusters
The partnership is hitting the ground running by targeting two of the most lucrative and high-profile biologics in the pharmaceutical industry: Roche’s Polivy (polatuzumab vedotin) and Amgen’s Tepezza (teprotumumab).
Polatuzumab Vedotin (Polivy)
As an antibody-drug conjugate (ADC), Polivy represents a significant challenge and opportunity for the biosimilars market. It utilizes a microtubule-disrupting payload, monomethyl auristatin E, to target CD79b-expressing B cells in patients with diffuse large B-cell lymphoma. With 2025 sales reaching CHF 1.47 billion—a 38% increase—the commercial demand for a lower-cost alternative is clear. By including an ADC in its development pipeline, Fresenius is signaling that it is moving beyond simple monoclonal antibodies to tackle more complex, high-value modalities.
Teprotumumab (Tepezza)
Used in the treatment of thyroid eye disease, a debilitating autoimmune condition, Tepezza has been a cornerstone of Amgen’s portfolio. While its 2025 U.S. sales saw a slight contraction of 4% to $1.758 billion, it remains a blockbuster asset. Developing a biosimilar for this monoclonal antibody will allow Fresenius to enter the specialized niche of rare autoimmune disorders, further diversifying its therapeutic footprint.
Implications for the Broader Industry
The Fresenius-WuXi deal reflects a wider, structural shift in how Western pharmaceutical giants interact with Chinese drug developers. We are seeing a move away from traditional licensing models toward "service-based" development partnerships.
This mirrors recent trends, such as the October 2026 agreement between Roche and Hansoh Pharma, where Roche targeted cancer candidates for Hansoh to build into ADCs. However, the Fresenius deal is distinct: by operating on a fee-for-service basis, Fresenius avoids the heavy royalty structures that often dilute the long-term profitability of such partnerships. By keeping all product economics in-house, Fresenius is aggressively positioning itself to capture the full margin of the biosimilars it brings to market.
Expansion of Therapeutic Scope
Currently, Fresenius Kabi’s U.S. portfolio is concentrated on heavy hitters like Humira, Prolia, Xgeva, Stelara, Neulasta, and Actemra. The new partnership is slated to expand this reach into 13 distinct therapeutic areas. Specifically, Fresenius plans to move into:
- Neurology
- Nephrology
- Cardiopulmonary medicine
These additions will augment its existing strongholds in oncology, immunology, and gastroenterology, transforming the company into a comprehensive biopharmaceutical player.
Official Responses and Corporate Outlook
In a statement regarding the deal, Fresenius CEO Michael Sen underscored the urgency of the move: "We are doubling down on our Biopharma business. With this agreement, we are gaining access to development capabilities in a market where speed and scale are of the essence."
The financial implications are also being closely monitored by stakeholders. Fresenius has stated that the agreement will be funded through operating cash flow, maintaining their existing guidance for the full-year 2026. Management has further indicated that the scale of this deal will likely cause them to revise their long-term Biopharma ambitions upward, viewing the partnership as a critical catalyst for the 2030 revenue targets.
Challenges and Future Outlook
While the potential for growth is significant, the path forward is not without risks. The biosimilars market is notoriously competitive, with pricing pressures and regulatory hurdles often complicating the road to commercialization. Furthermore, developing ADCs and bispecific antibodies requires a level of technical precision that pushes the boundaries of traditional biosimilar manufacturing.
However, by offloading the technical "heavy lifting" to WuXi Biologics—a company with a proven track record in global compliance and high-throughput development—Fresenius is effectively de-risking its own R&D pipeline. The modular nature of the agreement, which allows Fresenius to greenlight candidates one by one over the next decade, provides a built-in "off-ramp" should market conditions or clinical efficacy data change for any specific molecule.
As the industry moves toward 2030, all eyes will be on the execution of these first two programs. If Fresenius can successfully navigate the transition from development to market for Polivy and Tepezza biosimilars, they will have established a blueprint for the next generation of biopharmaceutical manufacturing, potentially setting the standard for how global healthcare firms manage the race to market for off-patent biologics.
This agreement is more than just a contract; it is a declaration of intent. Fresenius is betting its future on the idea that in the world of biologics, the company that controls the pipeline and the manufacturing speed will ultimately define the market. With 37 potential candidates in the wings, the competition is officially on notice.
About the Author
